Time for a change and to adopt a novel molecular genomic approach in NETs.
Andrew S. Paulson M.D.
Bodei, L., E. Liu, S. Paulson, A. Gulati, J. Freudman, W. Grosh, S. Kafer, P. C. Wickremesinghe and R. R. Salem (2019). “Time for a change and to adopt a novel molecular genomic approach in NETs.” Nat Rev Clin Oncol Feb 26. [Epub ahead of print].
We read with interest the News and Views article by Rindi and Wiedenmann (Neuroendocrine neoplasia goes molecular — time for a change. Nat. Rev. Clin. Oncol. 16, 149–150 (2018)), two notable and eminent authorities in the field of genomic medicine. Despite the concerns raised by these experts, the registry study discussed in their article unequivocally demonstrated the clinical utility of the NETest liquid biopsy assay in the ‘real-world’ setting. NETest scores enabled accurate prediction (100%) of disease progression and had a 98% correlation with response to therapy, reducing the requirement to perform an imaging test in 40% of patients . . . The following factual inaccuracies were stated in the News and Views by Rindi and Wiedenmann: that the Response Evaluation Criteria in Solid Tumors (RECIST) always enable an accurate assessment of NET progression; that our data should be viewed cautiously owing to tumour heterogeneity; that we provided no sensitivity data; that patient management depends on a multidisciplinary team (MDT) approach; and that the cost–benefit ratio of NETest is unfavourable. (Excerpt from correspondence.)